1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
2. Kim SS, Ruiz VE, Carroll JD, Moss SF. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett 2011; 305(2):
228-238.
3. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347(15): 1175-1186.
4. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 362(17): 1597-1604.
5. Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345(11): 784-789.
6. Cho SJ, Choi IJ, Kim CG, Lee JY, Kook MC, Seong MW, Park SR, Lee JS, Kim YW, Ryu KW, Lee JH, Nam BH, Park YI. Helicobacter pylori seropositivity is associated with gastric cancer regardless of tumor subtype in Korea. Gut Liver 2010; 4(4): 466-474.
7. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13(6):
607-615.
8. Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter
pylori-negative gastric cancer among Japanese. Helicobacter 2011; 16(6): 415-419.
9. De Falco M, Lucariello A, Iaquinto S, Esposito V, Guerra G, De Luca A. Molecular mechanisms of helicobacter pylori pathogenesis. J Cell Physiol 2015; 230(8): 1702-1707.
10. Lertpiriyapong K, Whary MT, Muthupalani S, Lofgren JL, Gamazon ER, Feng Y, Ge Z, Wang TC, Fox JG. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis. 2014; Gut 63(1): 54-63.
11. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human
c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986; 232:
1644-1646.
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:
177-182.
13. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015; 34: 157-164.
14. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol. 2013; 19: 2171-2178.
15. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012; 23:
2656-2662.
16. Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, et al. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers. J Gastrointest Surg. 2015; 19: 1565-1571.
17. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015; 18: 691-697.
18. Abrahão-Machado LF, Jácome AA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JH, Scapulatempo-Neto C. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol. 2013; 19: 6438-6446.
19. Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012; 3: 137-144.
20. Yoo MW, Han HS, Cho YH, Lee HG, Kim JH, Bang HY, Lee KY, Yoon SY. Is Helicobacter Pylori associated with Her2/neu Overexpression Y in Gastric Cancer Patients who Underwent Curative Resection? Hepatogastroenterology, 2014. 61(131): 858-62.
21. Hadi AA, Hindawi AE, Hareedy A, et al. Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients. Open Access Macedonian Journal of Medical Sciences. 2016; 4(4): 535-542. doi: 10.3889/oamjms. 2016.104.
22. Shun CT, Wu MS, Lin JT, Chen SY, Wang HP, Lee WJ, Wang TH, Chuang SM. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology, 1997. 44(14): 604-9.
23. Laboissiere RS, Buzelin MA, Balabram D, De Brot M, Nunes CB, Rocha RM, Cabral MM, Gobbi H. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol, 2015. 15: 157.
24. Chong VH, Telisinghe PU, Tan J, Abdullah MS, Chong CF.Profile of HER2 +ve Gastric Cancers in Brunei Darussalam. Asian Pac J Cancer Prev, 2016. 17(5): 2555-8.
25. Lee KE, Lee H-J, Kim YH, Yu HJ, Yang H-K, Kim W-H, Lee KU, Choe KJ, Kim J-P. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003; 33: 173-9.
26. Kim W, Hwang I, Kim MJ, Jang SJ. Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci 2009; 24: 1158-64.
27. Choi JS, Kim MA, Lee HE, Lee HS, Kim WH. Mucinous gastric carcinomas. Cancer 2009; 115: 3581-90.
28. Yan B, Yau EX, Omar SB, Ong CW, Pang B, Yeoh KG, Salto-Tellez M. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010; 63: 839-42.
29. Vizoso FJ, Corte MD, Alvarez A, García I, del Casar JM, Bongera M, González LO, García-Muñiz JL, Allende MT. Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance. Int J Biol Markers 2004; 19: 268-74.
